AI assistant
Quantum Genomics — Report Publication Announcement 2014
Nov 5, 2014
1617_iss_2014-11-05_e75f04b9-1a3f-46de-a226-3bdfefe4f88b.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
Massy – November 5th , 2014
Publication of an independent equity research by Aurgalys
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that Aurgalys, an equity research firm dedicated to life sciences, initiated the coverage of the company.
Their first financial analysis note, entitled «Quantum Genomics could revolutionize the hypertension market», is available on the website of Quantum Genomics (wwww.quantumgenomics.com), Investors section, and on Aurgalys website (www.aurgalys.com).
Click on equity research to consult it:
About Quantum Genomics
Contacts
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).
| Quantum Genomics Lionel Ségard |
Quantum Genomics Marc Karako |
ACTUS Jean-Michel Marmillon |
|---|---|---|
| CEO | CFO - Investor relations | Press relations |
| (+33) 1 60 13 76 80 | (+33) 1 60 13 76 84 | (33) 1 53 67 07 80 |
| [email protected] | [email protected] |